CompletedNCT05886582
Rotigotine added to behavioral support for cocaine use
About this title
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Read the official source — NCT05886582Medication studyAges 25–70United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 25 years to 70 years.
- Listed locations
- RichmondSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 11, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Virginia Commonwealth University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 25 Years to 70 Years
- Official registry ID
- NCT05886582
- Official title
Show the full official title
Phase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Richmond
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Virginia Commonwealth University, a university.
Did this study involve medication?
Yes. The study involved medication, including Rotigotine Transdermal System [Neupro] and Placebo.
Who was this study for?
Listed age limits: 25 years to 70 years.
